Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy

Raquel Cabrera-Pérez, Ferran Vila-Julià, Michio Hirano, Federico Mingozzi, Javier Torres-Torronteras, Ramon Martí

    Research output: Contribution to journalArticleResearch

    4 Citations (Scopus)

    Abstract

    © 2019 by Mary Ann Liebert, Inc. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a devastating disease caused by mutations in TYMP, which encodes thymidine phosphorylase (TP). In MNGIE patients, TP dysfunction results in systemic thymidine and deoxyuridine overload, which interferes with mitochondrial DNA replication. Preclinical studies have shown that gene therapy using a lentiviral vector targeted to hematopoietic stem cells or an adeno-associated virus (AAV) vector transcriptionally targeted to liver are feasible approaches to treat MNGIE. Here, we studied the effect of various promoters (thyroxine-binding globulin [TBG], phosphoglycerate kinase [PGK], hybrid liver-specific promoter [HLP], and alpha-1-antitrypsin [AAT]) and DNA configuration (single stranded or self complementary) on expression of the TYMP transgene in the AAV8 serotype in a murine model of MNGIE. All vectors restored liver TP activity and normalized nucleoside homeostasis in mice. However, the liver-specific promoters TBG, HLP, and AAT were more effective than the constitutive PGK promoter, and the self-complementary DNA configuration did not provide any therapeutic advantage over the single-stranded configuration. Among all constructs, only AAV-AAT was effective in all mice treated at the lowest dose (5 × 1010 vector genomes/kg). As use of the AAT promoter will likely minimize the dose needed to achieve clinical efficacy as compared to the other promoters tested, we propose using the AAT promoter in the vector eventually designed for clinical use.
    Original languageEnglish
    Pages (from-to)985-998
    JournalHuman Gene Therapy
    Volume30
    DOIs
    Publication statusPublished - 1 Aug 2019

    Keywords

    • AAV
    • mitochondria
    • MNGIE
    • promoter
    • thymidine
    • TYMP

    Fingerprint Dive into the research topics of 'Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy'. Together they form a unique fingerprint.

  • Cite this

    Cabrera-Pérez, R., Vila-Julià, F., Hirano, M., Mingozzi, F., Torres-Torronteras, J., & Martí, R. (2019). Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy, 30, 985-998. https://doi.org/10.1089/hum.2018.217